The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis

Overview

Journal JNCI Cancer Spectr

Publisher Oxford University Press

Specialty Oncology

Date 2019 Jul 31

PMID 31360833

Citations 8

Authors

Xun Cao

Yaopan Wu

Jing Wang

Kuiyuan Liu

Xin Wang

Affiliations

Soon will be listed here.

Abstract

Background: Most data suggest that cancer patients with diabetes have worse outcomes, which may be reversed with metformin. Metformin might modulate the clinical outcomes of diabetic cancer patients. We performed a systematic review and meta-analysis based on published studies over the past five years to summarize the effects of metformin on diabetic cancer patients.

Methods: We systematically searched for studies that were published over the past five years. Then, we evaluated these studies for inclusion and extracted the relevant data. The summary risk estimates for the association between metformin treatment and all-cause mortality (ACM) and cancer-specific mortality (CSM) were analyzed using random or fixed-effects models. Stratified analyses by cancer site and country were also conducted.

Results: Based on the 42 studies included in our analysis (37 015 diabetic cancer patients), we found a significant benefit associated with metformin treatment on survival corresponding to 27% and 26% reductions in ACM (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.68 to 0.79, < .001) and CSM (HR = 0.74, 95% CI = 0.64 to 0.86, < .001), respectively. The ACM rates for colorectal cancer, endometrial cancer, breast cancer, prostate cancer, and ovarian cancer showed significant benefits associated with metformin treatment in our stratified analyses by cancer site. Stratified analyses by cancer site also showed a significant reduction in CSM for breast cancer. This association between metformin treatment and reduced CSM for diabetic breast cancer patients was also observed in our country subgroup analyses.

Conclusions: We found an association between metformin exposure and reduced ACM and CSM in diabetic patients with cancer. Our findings suggest that metformin treatment could be an effective treatment option for diabetic cancer patients.

Citing Articles

The association between prescription drugs and colorectal cancer prognosis: a nationwide cohort study using a medication-wide association study.

Woo H, Jeong S, Shin A BMC Cancer. 2023; 23(1):643.

PMID: 37430209 PMC: 10334631. DOI: 10.1186/s12885-023-11105-9.

Metformin and long non-coding RNAs in breast cancer.

Gholami M, Klashami Z, Ebrahimi P, Mahboobipour A, Farid A, Vahidi A J Transl Med. 2023; 21(1):155.

PMID: 36849958 PMC: 9969691. DOI: 10.1186/s12967-023-03909-x.

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study.

Lee C, Heckman-Stoddard B, Dabelea D, Gadde K, Ehrmann D, Ford L Diabetes Care. 2021; 44(12):2775-2782.

PMID: 34697033 PMC: 8669534. DOI: 10.2337/dc21-1046.

Insulin Resistance and Cancer: In Search for a Causal Link.

Chiefari E, Mirabelli M, La Vignera S, Tanyolac S, Foti D, Aversa A Int J Mol Sci. 2021; 22(20).

PMID: 34681797 PMC: 8540232. DOI: 10.3390/ijms222011137.

The Effect of Metformin on Survival Outcomes of Non-Metastatic Breast Cancer Patients with Type 2 Diabetes.

Behrouzi B, Zokaasadi M, Mohagheghi M, Emami A, Sadighi S Asian Pac J Cancer Prev. 2021; 22(2):611-616.

PMID: 33639681 PMC: 8190344. DOI: 10.31557/APJCP.2021.22.2.611.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Al Hilli M, Bakkum-Gamez J, Mariani A, Cliby W, Mc Gree M, Weaver A . The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2015; 140(2):270-6. DOI: 10.1016/j.ygyno.2015.11.019. View

Staels B . Metformin and pioglitazone: Effectively treating insulin resistance. Curr Med Res Opin. 2006; 22 Suppl 2:S27-37. DOI: 10.1185/030079906X112732. View

Chen T, Lin C, Huang P, Wen C . Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011; 26(5):858-65. DOI: 10.1111/j.1440-1746.2011.06664.x. View

Richardson L, Pollack L . Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2(1):48-53. DOI: 10.1038/ncponc0062. View

Oliveras-Ferraros C, Vazquez-Martin A, Menendez J . Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle. 2009; 8(10):1633-6. DOI: 10.4161/cc.8.10.8406. View

Bayraktar S, Hernadez-Aya L, Lei X, Meric-Bernstam F, Litton J, Hsu L . Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2011; 118(5):1202-11. PMC: 3207034. DOI: 10.1002/cncr.26439. View

El-Benhawy S, El-Sheredy H . Metformin and survival in diabetic patients with breast cancer. J Egypt Public Health Assoc. 2014; 89(3):148-53. DOI: 10.1097/01.EPX.0000456620.00173.c0. View

He X, Esteva F, Ensor J, Hortobagyi G, Lee M, Yeung S . Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2011; 23(7):1771-80. PMC: 3387820. DOI: 10.1093/annonc/mdr534. View

10.

Bensimon L, Yin H, Suissa S, Pollak M, Azoulay L . The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev. 2014; 23(10):2111-8. DOI: 10.1158/1055-9965.EPI-14-0056. View

11.

Mc Menamin U, Murray L, Hughes C, Cardwell C . Metformin use and survival after colorectal cancer: A population-based cohort study. Int J Cancer. 2015; 138(2):369-79. DOI: 10.1002/ijc.29720. View

12.

Spratt D, Zhang C, Zumsteg Z, Pei X, Zhang Z, Zelefsky M . Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013; 63(4):709-16. PMC: 4034673. DOI: 10.1016/j.eururo.2012.12.004. View

13.

Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J . Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumour Biol. 2013; 35(3):2035-45. DOI: 10.1007/s13277-013-1270-5. View

14.

Kaushik D, Karnes R, Eisenberg M, Rangel L, Carlson R, Bergstralh E . Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 2013; 32(1):43.e1-7. PMC: 4006350. DOI: 10.1016/j.urolonc.2013.05.005. View

15.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

16.

Suissa S . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2007; 167(4):492-9. DOI: 10.1093/aje/kwm324. View

17.

Nayan M, Bhindi B, Yu J, Hermanns T, Mohammed A, Hamilton R . The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol Oncol. 2015; 33(9):386.e7-13. DOI: 10.1016/j.urolonc.2015.05.024. View

18.

Oppong B, Pharmer L, Oskar S, Eaton A, Stempel M, Patil S . The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med. 2014; 3(4):1025-34. PMC: 4303170. DOI: 10.1002/cam4.259. View

19.

Peeters P, Bazelier M, Vestergaard P, Leufkens H, Schmidt M, de Vries F . Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf. 2013; 8(5):357-63. PMC: 5421139. DOI: 10.2174/15680266113136660069. View

20.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View